Evie Ring Product & Launch - The Evie Ring is launching in November 2023 and is available in US sizes 5-12[55, 56] - The Evie Ring is priced at $269 with no monthly subscription[61] - The Evie Ring has successfully filed for FDA clearance on SpO2 & HR data in July 2023[65] Market Opportunity & Need - The global wearable market is projected to reach $145 billion by 2027[30] - 92% of women feel unprepared for menopause[7] - Condition Management represents a $14 billion opportunity, Corporate Wellness $20 billion, and Clinical Trials $2 billion[49] Technology & Innovation - Movano Health has 20+ years of smart antenna experience and 200+ issued patents[1, 99] - Movano Health's patented System-on-a-Chip integrates the power of 4 chips in 1 for blood pressure and glucose monitoring[104] - Evie Ring Q4 Hypoxia Pivotal Trial Results: SpO2 RMSE of 2.13% compared to FDA benchmark of <3.5% and Heart Rate RMSE of ~2 bpm[67] Consumer Demand & Engagement - As of August 14, 2023, Evie Ring has more than 100,000 signups and over 600,000 visitors to eviering.com[83] - 27.4M+ impressions served by Evie digital campaigns since January[86]

[PART I – FINANCIAL INFORMATION](index=3&type=section&id=PART%20I%20%E2%80%93%20FINANCIAL%20INFORMATION) [Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) Movano Inc. reported no revenue, consistent with its development-stage status, with net loss increasing to $7.3 million for Q2 2023 and $14.4 million for the first six months, while cash stood at $14.5 million as of June 30, 2023, bolstered by public offerings, highlighting a significant accumulated deficit and a 'going concern' warning [Condensed Consolidated Balance Sheets](index=3&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of June 30, 2023, Movano's total assets increased to $17.6 million from $13.2 million at year-end 2022, primarily due to a rise in cash and cash equivalents to $14.5 million, with total liabilities decreasing slightly to $4.7 million and stockholders' equity improving to $12.8 million, though the accumulated deficit grew to $109.5 million Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | June 30, 2023 | December 31, 2022 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $14,472 | $10,759 | | Total current assets | $16,086 | $11,646 | | **Total assets** | **$17,573** | **$13,243** | | **Liabilities & Equity** | | | | Total current liabilities | $4,553 | $4,978 | | Total liabilities | $4,745 | $5,328 | | Accumulated deficit | ($109,460) | ($95,097) | | **Total stockholders' equity** | **$12,828** | **$7,915** | [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) For the three months ended June 30, 2023, the company reported a net loss of $7.3 million, or ($0.17) per share, compared to a net loss of $6.9 million, or ($0.21) per share, for the same period in 2022, with the six-month net loss at $14.4 million in 2023 versus $13.8 million in 2022, driven by higher sales, general, and administrative expenses Statement of Operations Highlights (in thousands, except per share data) | Metric | Q2 2023 | Q2 2022 | Six Months 2023 | Six Months 2022 | | :--- | :--- | :--- | :--- | :--- | | Research and development | $4,171 | $4,112 | $8,065 | $8,703 | | Sales, general and administrative | $3,213 | $2,734 | $6,522 | $5,081 | | **Loss from operations** | **($7,384)** | **($6,846)** | **($14,587)** | **($13,784)** | | **Net loss** | **($7,267)** | **($6,868)** | **($14,363)** | **($13,800)** | | Net loss per share, basic and diluted | ($0.17) | ($0.21) | ($0.36) | ($0.42) | [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) For the six months ended June 30, 2023, net cash used in operating activities was $14.0 million, while net cash provided by financing activities was $17.7 million, primarily from public offerings of common stock, resulting in a net increase in cash and cash equivalents of $3.7 million, bringing the period-end balance to $14.5 million Cash Flow Summary for Six Months Ended June 30 (in thousands) | Cash Flow Activity | 2023 | 2022 | | :--- | :--- | :--- | | Net cash used in operating activities | ($13,964) | ($12,153) | | Net cash provided by (used in) investing activities | ($39) | $11,548 | | Net cash provided by financing activities | $17,716 | $19 | | **Net increase / (decrease) in cash** | **$3,713** | **($586)** | | **Cash and cash equivalents at end of period** | **$14,472** | **$17,089** | [Notes to Condensed Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Key notes detail the company's development-stage nature, reliance on equity financing, and substantial doubt about its ability to continue as a going concern, with two public offerings in February and June 2023 raising net proceeds of approximately $6.7 million and $8.1 million respectively, also covering stock-based compensation, warrants, and lease commitments - The company is a development-stage entity that has not yet recorded any revenues and has incurred losses since inception, with its ability to continue as a **going concern in substantial doubt**[23](index=23&type=chunk)[27](index=27&type=chunk) - In February 2023, the company raised net proceeds of approximately **$6.7 million** from a public offering of common stock and warrants[24](index=24&type=chunk)[68](index=68&type=chunk) - In June 2023, the company raised net proceeds of approximately **$8.1 million** from a public offering of common stock[25](index=25&type=chunk)[69](index=69&type=chunk) - As of June 30, 2023, the company had non-cancelable contractual commitments of **$0.4 million**, primarily with vendors, due within one to twelve months[116](index=116&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=26&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's development-stage status focused on its Evie Ring product and proprietary SoC, with operating losses increasing to $7.4 million in Q2 2023 from $6.8 million in Q2 2022 due to higher SG&A expenses, and despite raising $17.7 million from financing activities, existing cash is not sufficient to fund operations for the next twelve months, raising substantial doubt about its ability to continue as a going concern - The company's initial product is the **Evie Ring**, a wearable designed for women, for which it filed a **510(k) submission** with the FDA in July 2023 for its pulse oximeter[125](index=125&type=chunk)[126](index=126&type=chunk) - Movano is also developing a proprietary **System-on-a-Chip (SoC)** for **non-invasive continuous glucose monitoring (CGM)** and **cuffless blood pressure monitoring**[127](index=127&type=chunk) Comparison of Operating Results (in thousands) | Metric | Q2 2023 | Q2 2022 | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Research and development | $4,171 | $4,112 | $59 | 1% | | Sales, general and administrative | $3,213 | $2,734 | $479 | 18% | | **Loss from operations** | **($7,384)** | **($6,846)** | **($538)** | **-8%** | | **Net loss** | **($7,267)** | **($6,868)** | **($399)** | **-6%** | - The company's cash of **$14.5 million** is not expected to be sufficient to fund operations for the next twelve months, raising **substantial doubt** about its ability to continue as a going concern[140](index=140&type=chunk)[145](index=145&type=chunk) - During the first six months of 2023, the company sold **2,200,746 shares** through its At-the-Market (ATM) program for net proceeds of **$2.9 million**, with approximately **$44.7 million** remaining available under the program[141](index=141&type=chunk)[73](index=73&type=chunk) [Quantitative and Qualitative Disclosure About Market Risk](index=33&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosure%20About%20Market%20Risk) As a smaller reporting company, Movano Inc. is not required to provide the information for this item - The company is **not required** to provide information on market risk as it qualifies as a **smaller reporting company**[155](index=155&type=chunk) [Controls and Procedures](index=33&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures were not effective as of June 30, 2023, due to a previously disclosed material weakness in internal control over financial reporting related to the ineffective design and operation of financial close and reporting controls, with no material changes to internal controls made during the quarter - Management concluded that disclosure controls and procedures were **not effective** as of June 30, 2023[157](index=157&type=chunk) - The ineffectiveness is due to a **material weakness** identified at December 31, 2022, related to the financial close and reporting controls, which has **not yet been fully remediated**[159](index=159&type=chunk) [PART II – OTHER INFORMATION](index=35&type=section&id=PART%20II%20%E2%80%93%20OTHER%20INFORMATION) [Legal Proceedings](index=35&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently a party to any pending legal proceedings that are expected to have a material adverse effect on its business or financial condition - Movano is **not currently a party** to any **material pending legal proceedings**[164](index=164&type=chunk) [Risk Factors](index=35&type=section&id=Item%201A.%20Risk%20Factors) This section refers to the risk factors previously disclosed in the company's Annual Report on Form 10-K for the year ended December 31, 2022, and subsequent quarterly reports - For a discussion of risks and uncertainties, readers are **referred to Part I, 'Item 1A. Risk Factors' in the 2022 Form 10-K**[165](index=165&type=chunk) [Recent Sales of Unregistered Securities; Use of Proceeds from Registered Securities](index=35&type=section&id=Item%202.%20Recent%20Sales%20of%20Unregistered%20Securities%3B%20Use%20of%20Proceeds%20from%20Registered%20Securities) This item is not applicable for the reporting period - **Not applicable**[166](index=166&type=chunk) [Defaults Upon Senior Securities](index=35&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) This item is not applicable for the reporting period - **Not applicable**[167](index=167&type=chunk) [Mine Safety Disclosures](index=35&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable for the reporting period - **Not applicable**[168](index=168&type=chunk) [Other Information](index=35&type=section&id=Item%205.%20Other%20Information) During the second quarter of 2023, none of the company's directors or executive officers adopted or terminated a Rule 10b5-1 trading plan or any non-Rule 10b5-1 trading arrangement - **No directors or executive officers adopted or terminated any Rule 10b5-1(c) trading plans** during the three months ended June 30, 2023[169](index=169&type=chunk) [Exhibits](index=36&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including the CEO and CFO certifications (Exhibits 31.1, 31.2, 32.1) and Inline XBRL documents - The report includes **CEO and CFO certifications** pursuant to Sarbanes-Oxley Act Sections 302 and 906, along with **Inline XBRL data files**[170](index=170&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 001-40254 MOVANO INC. (State of incorporation) (I.R.S. Employer Delaware 26-0579295 Identification No.) 6800 Koll Center Parkway, Pleasanton, CA 94566 (Address of pr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission file number: 001-40254 MOVANO INC. (Exact name of registrant as specified in its charter) Delaware 82-4233771 (State of incorporatio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 001-40254 MOVANO INC. (Exact name of registrant as specified in its charter) Delaware 26-0579295 (State of incorporation) (I.R.S. Employer Identification No.) 6800 Ko ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 001-40254 MOVANO INC. (Exact name of registrant as specified in its charter) | Delaware | 26-0579295 | | --- | --- | | (State of incorporation) | (I.R.S. Employer | ...

Part I [Business](index=6&type=section&id=Item%201.%20Business) Movano Inc. is a development-stage company creating a healthcare platform with the Movano Ring, targeting FDA clearance for non-invasive continuous glucose and cuffless blood pressure monitoring - Movano is developing a healthcare platform based on proprietary RF technology, with its initial product being the Movano Ring, a smart ring designed for women[16](index=16&type=chunk)[17](index=17&type=chunk)[18](index=18&type=chunk) - The company's long-term goal is to achieve Class II FDA clearance for its technology to provide non-invasive continuous glucose monitoring (CGM) and cuffless blood pressure monitoring[19](index=19&type=chunk)[61](index=61&type=chunk) - Movano has conducted several IRB-approved clinical trials to collect data for refining its blood pressure and glucose monitoring algorithms, completing its largest blood pressure trial on **110 participants** in December 2021[49](index=49&type=chunk)[52](index=52&type=chunk)[53](index=53&type=chunk) - As of December 31, 2021, the company's intellectual property portfolio includes **6 issued patents** and **42 pending U.S. patent applications**[59](index=59&type=chunk) - The company faces competition from major players in the wellness market (Apple, Samsung, Oura), CGM market (DexCom, Abbott), and blood pressure monitoring market (OMRON, Philips)[77](index=77&type=chunk)[78](index=78&type=chunk)[79](index=79&type=chunk) [Risk Factors](index=17&type=section&id=Item%201A.%20Risk%20Factors) The company faces substantial risks including limited operating history, ongoing losses, capital needs, intense competition, regulatory hurdles, and reliance on third parties - The company is a development-stage entity with no revenue history, an accumulated deficit of approximately **$64.8 million** as of December 31, 2021, and may never achieve profitability[95](index=95&type=chunk)[96](index=96&type=chunk) - There is substantial uncertainty about the company's ability to continue as a going concern, as its current cash is insufficient to complete the development and commercialization of its proposed solution[97](index=97&type=chunk) - The business is highly dependent on the success of its proposed solution, which requires substantial clinical development and regulatory clearance or approval from the FDA, which may be difficult to achieve[113](index=113&type=chunk)[128](index=128&type=chunk) - The company expects to depend on third-party OEMs, VARs, and distributors for the design, manufacture, and sale of its products, but currently has no such relationships[114](index=114&type=chunk)[115](index=115&type=chunk) - As an "emerging growth company," Movano is subject to reduced disclosure requirements, which may make its common stock less attractive to investors[165](index=165&type=chunk) [Unresolved Staff Comments](index=36&type=section&id=Item%201B.%20Unresolved%20Staff%20Comments) There are no unresolved staff comments - Not applicable[172](index=172&type=chunk) [Properties](index=36&type=section&id=Item%202.%20Properties) The company's principal office is located in Pleasanton, California - The company's principal office is located at 6800 Koll Center Parkway, Pleasanton, California[173](index=173&type=chunk) [Legal Proceedings](index=36&type=section&id=Item%203.%20Legal%20Proceedings) The company is not currently a party to any material legal proceedings - The company is not currently involved in any pending legal proceedings expected to have a material adverse effect on its business[174](index=174&type=chunk) [Mine Safety Disclosures](index=36&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This section is not applicable to the company - Not applicable[175](index=175&type=chunk) Part II [Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](index=37&type=section&id=Item%205.%20Market%20for%20Registrant%27s%20Common%20Equity%2C%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities) Movano's common stock began trading on Nasdaq in March 2021, with the company having never paid dividends and no material change in IPO proceeds use - The company's common stock has been listed on the Nasdaq Capital Market under the symbol "**MOVE**" since **March 23, 2021**[178](index=178&type=chunk) - The company has never paid cash dividends and does not plan to in the foreseeable future, retaining any future earnings for business reinvestment[180](index=180&type=chunk) - The company's Registration Statement on Form S-1 (Reg. No. 333-252671) was declared effective on **March 22, 2021**, for its IPO[182](index=182&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=38&type=section&id=Item%207.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Movano's net loss increased to **$21.8 million** in 2021 due to higher R&D and G&A expenses, with **$33.6 million** in cash deemed sufficient for 12 months of operations but not full product commercialization | | Year Ended December 31, | Change | |---|---|---|---| | | **2021** | **2020** | **$** | | **(in thousands)** | | | | | Research and development | $13,427 | $8,373 | $5,054 | | General and administrative | $6,376 | $2,734 | $3,642 | | **Total operating expenses** | **$19,803** | **$11,107** | **$8,696** | | Loss from operations | ($19,803) | ($11,107) | ($8,696) | | **Net loss** | **($21,773)** | **($13,031)** | **($8,742)** | - The increase in R&D expenses was primarily due to a **$3.8 million** rise in employee compensation and a **$0.7 million** increase in other professional fees[218](index=218&type=chunk) - The increase in G&A expenses was mainly driven by a **$1.6 million** rise in employee and board compensation and a **$0.8 million** increase in professional and consulting fees[220](index=220&type=chunk) - As of December 31, 2021, the company had **$33.6 million** in cash, cash equivalents, and short-term investments, which it believes is sufficient to fund operations for at least **12 months**[193](index=193&type=chunk)[225](index=225&type=chunk) | | Year Ended December 31, | |---|---|---| | **(in thousands)** | **2021** | **2020** | | Net cash used in operating activities | ($16,183) | ($10,666) | | Net cash used in investing activities | ($16,699) | $0 | | Net cash provided by financing activities | $44,847 | $12,085 | [Quantitative and Qualitative Disclosures About Market Risk.](index=47&type=section&id=Item%207A.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk.) This section is not applicable to the company - Not applicable[239](index=239&type=chunk) [Financial Statements and Supplementary Data.](index=48&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data.) Audited consolidated financial statements for 2021 and 2020 are presented, highlighting the **March 2021 IPO** that raised **$44.3 million** and led to the conversion of preferred stock and convertible notes into common stock | | Dec 31, 2021 | Dec 31, 2020 | |---|---|---| | **(in thousands)** | | | | **Assets** | | | | Cash and cash equivalents | $17,675 | $5,710 | | Short-term investments | $15,921 | $0 | | **Total Assets** | **$36,265** | **$7,083** | | **Liabilities & Equity** | | | | Total current liabilities | $3,218 | $1,160 | | Total noncurrent liabilities | $317 | $13,985 | | **Total Liabilities** | **$3,535** | **$15,145** | | Total stockholders' equity (deficit) | $32,730 | ($40,880) | - In its **March 2021 IPO**, the company sold **9,775,000 shares** of common stock at **$5.00 per share**, raising net proceeds of **$44.3 million** after underwriting discounts and offering expenses[267](index=267&type=chunk) - Upon the IPO, all outstanding redeemable convertible preferred stock converted into **11,436,956 shares** of common stock[290](index=290&type=chunk)[336](index=336&type=chunk) - Upon the IPO, **$12.9 million** in principal and interest from convertible notes converted into **5,015,494 shares** of common stock[329](index=329&type=chunk)[341](index=341&type=chunk) - The company maintains a full valuation allowance against its net deferred tax assets of approximately **$9.0 million** due to uncertainty surrounding their realization[390](index=390&type=chunk) [Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.](index=85&type=section&id=Item%209.%20Changes%20in%20and%20Disagreements%20with%20Accountants%20on%20Accounting%20and%20Financial%20Disclosure.) There were no changes in or disagreements with accountants on accounting and financial disclosure - None[402](index=402&type=chunk) [Controls and Procedures.](index=85&type=section&id=Item%209A.%20Controls%20and%20Procedures.) As of December 31, 2021, management concluded that disclosure controls and procedures were ineffective due to a material weakness in financial close and reporting controls - Management concluded that as of **December 31, 2021**, the company's disclosure controls and procedures were ineffective[403](index=403&type=chunk) - A material weakness was identified related to the ineffective design and operation of financial close and reporting controls, though it did not result in any identified misstatements to the financial statements[404](index=404&type=chunk)[405](index=405&type=chunk) [Other Information.](index=85&type=section&id=Item%209B.%20Other%20Information.) This section is not applicable - Not applicable[408](index=408&type=chunk) [Disclosure Regarding Foreign Jurisdictions that Prevent Inspections](index=85&type=section&id=Item%209C.%20Disclosure%20Regarding%20Foreign%20Jurisdictions%20that%20Prevent%20Inspections) This section is not applicable - Not applicable[409](index=409&type=chunk) Part III [Directors, Executive Officers and Corporate Governance.](index=86&type=section&id=Item%2010.%20Directors%2C%20Executive%20Officers%20and%20Corporate%20Governance.) The information required for this item is incorporated by reference from the company's Proxy Statement for its 2022 annual meeting of stockholders - Information is incorporated by reference to the Proxy Statement on Schedule 14A for the **2022 annual meeting of stockholders**[412](index=412&type=chunk) [Executive Compensation](index=86&type=section&id=Item%2011.%20Executive%20Compensation) The information required for this item is incorporated by reference from the company's Proxy Statement for its 2022 annual meeting of stockholders - Information is incorporated by reference to the Proxy Statement on Schedule 14A for the **2022 annual meeting of stockholders**[413](index=413&type=chunk) [Security Ownership of Certain Beneficial Owners and Management and Related Stockholders Matters.](index=86&type=section&id=Item%2012.%20Security%20Ownership%20of%20Certain%20Beneficial%20Owners%20and%20Management%20and%20Related%20Stockholders%20Matters.) The information required for this item is incorporated by reference from the company's Proxy Statement for its 2022 annual meeting of stockholders - Information is incorporated by reference to the Proxy Statement on Schedule 14A for the **2022 annual meeting of stockholders**[414](index=414&type=chunk) [Certain Relationships and Related Transactions, and Director Independence](index=86&type=section&id=Item%2013.%20Certain%20Relationships%20and%20Related%20Transactions%2C%20and%20Director%20Independence) The information required for this item is incorporated by reference from the company's Proxy Statement for its 2022 annual meeting of stockholders - Information is incorporated by reference to the Proxy Statement on Schedule 14A for the **2022 annual meeting of stockholders**[415](index=415&type=chunk) [Principal Accountant Fees and Services](index=86&type=section&id=Item%2014.%20Principal%20Accountant%20Fees%20and%20Services) The information required for this item is incorporated by reference from the company's Proxy Statement for its 2022 annual meeting of stockholders - Information is incorporated by reference to the Proxy Statement on Schedule 14A for the **2022 annual meeting of stockholders**[416](index=416&type=chunk) Part IV [Exhibits, Financial Statements and Schedules](index=87&type=section&id=Item%2015.%20Exhibits%2C%20Financial%20Statements%20and%20Schedules) This section lists financial statements, schedules, and an index of exhibits filed with the Form 10-K report, including corporate governance documents and material contracts - This item lists the financial statements and exhibits filed with the report, including corporate governance documents, incentive plans, and material contracts[419](index=419&type=chunk)[420](index=420&type=chunk)

Financial Data and Key Metrics Changes - Movano reported an operating loss of $6.3 million in Q4 2021, compared to an operating loss of $3.2 million in the same period last year [39] - For the full year 2021, the operating loss was $19.8 million, up from $11.1 million in 2020 [39] - The increase in losses was primarily due to team expansion, R&D initiatives, and costs associated with being a public company [40] Business Line Data and Key Metrics Changes - The company is preparing for the beta launch of its first commercial product, the Movano Ring, which is expected to be released in the second half of 2022 [12][40] - The Movano Ring will measure various health metrics and is designed specifically for women, addressing a gap in the wearable technology market [10][20] Market Data and Key Metrics Changes - Since the announcement of the Movano Ring, the company has received over 50,000 unique visitors to its website and more than 4,000 supportive messages from potential customers [17] - The media response to the Movano Ring has been overwhelmingly positive, with features in major outlets like TechCrunch and Forbes [15] Company Strategy and Development Direction - Movano aims to position itself at the intersection of medical technology and consumer devices, focusing on affordable health solutions [25][23] - The company is pursuing FDA clearances for its health monitoring capabilities, which include heart rate, blood oxygen, and respiration rate [12][54] - The strategy includes a subscription model to make the solution accessible to a wider audience while allowing for reinvestment in product features [58] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's trajectory and the market opportunity, emphasizing the importance of capital deployment and operating efficiency [42][46] - The CEO highlighted the need for healthcare to become more consumer-oriented and the potential for the Movano Ring to help a large population manage their health proactively [61][62] Other Important Information - The company has made significant progress in technology development, including the completion of critical studies for FDA clearances [26][30] - Key strategic hires have been made to strengthen the team, including individuals with experience from Google Fitbit and Medtronic [34] Q&A Session Summary Question: What is the status of cash burn rate? - The cash burn was $5.7 million in Q4, with $33.6 million in cash equivalents at year-end. The company plans to invest in R&D and team expansion as it prepares for the beta launch [45][46] Question: How did the meetings with potential strategic partners at CES go? - The Movano Ring announcement generated significant interest from potential strategic partners across healthcare, consumer, and technology sectors, exceeding expectations [47] Question: What is the status of blood pressure and glucose algorithm development? - Progress has been made, but the company is not yet ready to file for FDA clearance. The focus is on improving data accuracy and developing algorithms [48][54] Question: Can you provide details on the beta launch, including pricing and subscription model? - There is high interest in beta testing, but specific details on pricing and subscription models are not yet available. The focus will be on thorough testing before launch [55][56] Question: What are the biggest takeaways after one year as CEO? - The CEO emphasized the importance of addressing chronic health conditions and the potential for the Movano Ring to help a large audience live healthier lives [60][62]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 001-40254 MOVANO INC. (Exact name of registrant as specified in its charter) (State of incorporation) (I.R.S. Employer Delaware 26-0579295 Identification No.) 68 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 001-40254 MOVANO INC. (Exact name of registrant as specified in its charter) (State of incorporation) (I.R.S. Employer Delaware 26-0579295 Identification No.) 6800 Ko ...